# Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

> **NCT06530784** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **PROCEDURE:** Cryoablation
- **DRUG:** PD-1 antibody and bevacizumab

## Key facts

- **NCT ID:** NCT06530784
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06530784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06530784, "Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06530784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*